Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Receivables (2016 - 2025)

Wave Life Sciences' Receivables history spans 9 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Receivables fell 10.27% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 10.27%, while the annual FY2025 figure was $1.3 million, 10.27% down from the prior year.
  • Receivables reached $1.3 million in Q4 2025 per WVE's latest filing, down from $10.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $60.0 million in Q1 2021 to a low of $1.3 million in Q4 2025.
  • Average Receivables over 4 years is $14.0 million, with a median of $7.0 million recorded in 2023.
  • Peak YoY movement for Receivables: tumbled 93.26% in 2024, then rose 25.35% in 2025.
  • A 4-year view of Receivables shows it stood at $22.5 million in 2021, then fell by 6.28% to $21.1 million in 2023, then crashed by 93.26% to $1.4 million in 2024, then decreased by 10.27% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Receivables are $1.3 million (Q4 2025), $10.0 million (Q3 2025), and $1.6 million (Q2 2025).